Impact of rapid molecular diagnostic tests on time to treatment initiation and outcomes in patients with multidrug-resistant tuberculosis, Tamil Nadu, India
Authors:
- 1 September 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 110 (9) , 534-541
Abstract
India is replacing culture and drug sensitivity testing (CDST) with rapid molecular tests for diagnosing MDR-TB. We assessed the impact of rapid tests on time to initiation of treatment and outcomes in patients with MDR-TB compared with CDST. A retrospective cohort study involving MDR-TB patients from six districts in Tamil Nadu state, who underwent CDST (2010–2011) and rapid tests (2012–2013). There were 135 patients in the CDST group and 389 in the rapid diagnostic test group. Median time from sputum receipt at the laboratory to initiation of MDR-TB treatment was 130 days (IQR 75–213) in the CDST group and 22 days (IQR 14–38) in the rapid diagnostic test group (p30 days (aRR 1.3, 95% CI 1.0–1.6). Rapid molecular diagnostic tests shortened the time to initiate treatment which was associated with reduced unfavourable outcomes in MDR-TB patients. This supports the policy to scale up these tests in India.Keywords
This publication has 21 references indexed in Scilit:
- Xpert® MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, ZimbabweThe International Journal of Tuberculosis and Lung Disease, 2016
- Evaluation of Xpert® MTB/RIF assay: diagnosis and treatment outcomes in rifampicin-resistant tuberculosisThe International Journal of Tuberculosis and Lung Disease, 2015
- Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients’ experiences in the era of rapid molecular diagnostic testsBMC Health Services Research, 2015
- Impact of Xpert MTB/RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised TrialPLOS Medicine, 2014
- Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trialThe Lancet, 2014
- Results from early programmatic implementation of Xpert MTB/RIF testing in nine countriesBMC Infectious Diseases, 2014
- Detecting Drug-Resistant TuberculosisMolecular Diagnosis & Therapy, 2011
- Rapid Molecular Detection of Tuberculosis and Rifampin ResistanceNew England Journal of Medicine, 2010
- GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysisEuropean Respiratory Journal, 2008
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007